NCT05759208View on ClinicalTrials.gov

The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

April 28, 2023

Primary Completion Date

December 15, 2023

Study Completion Date

December 15, 2023

Conditions
Dry Eye Disease
Interventions
DRUG

OK-101

Ophthalmic Solution

DRUG

Placebo

Placebo

Trial Locations (6)

28150

Core Inc., Shelby

38119

Total Eye Care, PA, Memphis

40206

Butchertown clinical Trials, Louisville

80907

Vision Institute, Colorado Springs

92663

Eye Research Foundation, Newport Beach

01810

Andover Eye Associates, Andover

Sponsors

Lead Sponsor

Okyo Pharma Ltd
All Listed Sponsors
collaborator

ORA, Inc.

INDUSTRY

lead

Okyo Pharma Ltd

INDUSTRY

NCT05759208 - The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease | Biotech Hunter | Biotech Hunter